EGFR and nonpapillary renal cell carcinoma: To better clarify how ADAM12-induced proliferation, migration, invasion and EMT were regulated via the EGFR/ERK signaling pathway, ccRCC cells were treated with gefitinib, an EGFR phosphorylation inhibitor.